UMN-02 pharmacological study results published in the October, 2008 volume of the Journal of Pharmacology and Experimental Therapeutics, a leading international academic journal, showed the involvement of 5-HT(2A) receptor activation in choline-deficient, 0.5% D,L-ethionine supplemented (CDE) diet-induced acute pancreatitis in mice. This research paper follows a previous presentation made at the annual Digestive Disease Week (DDW) conference held in May of 2008 in the USA. The data presented at DDW demonstrated the potential efficacy of selective 5-HT(2A) antagonist in acute pancreatitis. The most recent study results showed that UMN-02 ameliorated severe necrotizing acute pancreatitis in mice by inhibiting key inflammatory responses. Based on these experimental results, we believe that UMN-02, a highly specific 5-HT2A antagonist, could serve as a novel therapeutic for the treatment of not only of acute edematous pancreatitis, but also for various symptoms of pancreatitis.
References
Yamaguchi I, Hamada K, Yoshida M, Isayama H, Kanazashi S, and Takeuchi K. Risperidone attenuates local and systemic inflammatory responses to ameliorate diet-induced severe necrotic pancreatitis in mice: it may provide a new therapy for acute pancreatitis. J. Pharmacol. Exp. Ther. 2008 Oct. 1;[epub ahead of print].

http://www.ncbi.nlm.nih.gov/pubmed/18832108?ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum